Navigation Links
Newer Blood Thinners May Outperform Old Standbys
Date:11/18/2009

Studies found warfarin, Plavix bested by latest anti-clotting alternatives

WEDNESDAY, Nov. 18 (HealthDay News) -- After years of little progress, three new trials suggest that the latest generation of blood thinners may outperform the old standbys warfarin and clopidogrel (Plavix).

In one study, dabigatran etexilate (marketed as Pradax in Canada and Pradaxa in Europe; it is not yet approved in the United States) proved to be safe in preventing blood clots when patients were treated for acute coronary syndrome, a cluster of symptoms that might indicate a heart attack.

"Dabigatran seems to be safe on top of dual antiplatelet therapy [meaning aspirin and Plavix]," said study author Dr. Jonas Oldgren, chief physician in the department of cardiology at Uppsala University Hospital in Uppsala, Sweden. "It has already been shown to have superior efficacy compared with warfarin."

A previous trial had demonstrated that dabigatran outperformed warfarin in preventing strokes in patients with atrial fibrillation.

The current trial, to be presented Wednesday at the American Heart Association's annual meeting in Orlando, Fla., also saw a reduction in mortality, nonfatal heart attack and stroke, although it was not specifically designed to look at efficacy.

"Dabigatran appears to be superior to warfarin in terms of safety and more effective as well. This is the first alternative to warfarin that could signal a changing of the guard," said Dr. Bernard Gersh, a professor of medicine at the Mayo Clinic College of Medicine in Rochester, Minn. "I think there are still questions that need to be answered but it's fair to say that warfarin has been around for many, many years and everybody hates warfarin. Patients hate warfarin. Doctors hate warfarin. It's not the most convenient drug, but it's effective and it is cheap."

The trial involved more than 18,000 patients in 24 countries with acute coronary syndrome who were randomized to receive one of four doses of dabigatran, made by Boehringer Ingelheim, or a placebo. All participants were also taking aspirin and Plavix.

"It's premature to say that a drug like dabigatran will take the place of warfarin," Gersh said. "There will be a lot of discussion about cost and convenience. It's a twice-daily dose and there are some questions about a possible higher rate of heart attack. I don't think this is truly resolved yet, but I think we can say that for the first time we have seen a drug that certainly has the potential to be an alternative to warfarin, and maybe even superior."

Two other trials, both presented at the heart association meeting and published in the Nov. 18 issue of Circulation, looked at an anti-clotting pill called ticagrelor (Brilinta), comparing its performance with clopidogrel (Plavix). Brilinta, made by AstraZeneca, is also awaiting approval from the U.S. Food and Drug Administration.

Prior Brilinta studies found that it was better than Plavix in preventing new heart attacks and preventing deaths among patients who had already had a heart attack.

In the first of the two latest trials, both conducted by researchers at Sinai Hospital in Baltimore, 123 patients with stable coronary artery disease who were also taking aspirin were randomized to Brilinta, Plavix or a placebo for six weeks.

Brilinta evoked a response in patients who did not respond to Plavix. It also could be turned off faster, meaning patients could go into surgery right away if needed, and lasted longer.

The second Brilinta study showed that 98 patients who didn't respond to Plavix did respond to Brilinta.

All of this just signals the beginning of a new round of anti-clotting medications, experts said.

"There are several trials ongoing of other alternatives to warfarin. We will probably see results in the next two years," Gersh said.

More information

Visit the American Heart Association for more on blood thinners.



SOURCES: Bernard Gersh, M.D., professor, medicine, Mayo Clinic College of Medicine, Rochester, Minn.; Nov. 18, 2009, news conference with: Jonas Oldgren, M.D., chief physician, cardiology, Uppsala University Hospital, Uppsala, Sweden; Nov. 18, 2009, presentations, American Heart Association annual meeting, Orlando, Fla.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Newer antidepressants led to less, not more, teen suicides
2. Newer Antibiotic Speeds TB Healing
3. Newer radiation treatment easier for some throat cancer patients
4. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
5. Newer Sedative Might Help Patients on Ventilators
6. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
7. Newer Prostate Cancer Treatment Similar to Traditional Surgery
8. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
9. Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
10. First generation antipsychotic drugs as effective as newer ones in some children
11. Newer antipsychotics no better than older drug in treating child and adolescent schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... ... device compliance and commercialization, has just announced two more sessions of its “From ... engineering into risk management activities. Led by David Cronin, Cognition’s CEO, the half-hour ...
(Date:7/18/2017)... ... July 18, 2017 , ... The results of an international clinical trial, led in ... for a severe type of muscular dystrophy holds promise for a subgroup of patients. , ... McDonald and colleagues at 53 study sites in 18 countries describe the clinical benefit ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, ... "Due to menopause, I have frequent hot flashes, and I suffer from anxiety and ... way to keep cool while out and about." INSTA-FAN meets that need. , This ...
(Date:7/18/2017)... ... July 18, 2017 , ... Heritage Woods of Benton, a ... to 12:30 p.m. on Aug. 15. , The community, which is located at 1305 ... Medicaid, who need some help to maintain their independence. , The lunch menu will ...
(Date:7/18/2017)... ... 18, 2017 , ... FCPX LUT Berlin for Final Cut Pro X gives ... includes 60 different color-grade presets, giving FCPX users numerous options for adding different color ... each subject, plus much more. FCPX LUT Berlin is designed for any skill-level, from ...
Breaking Medicine News(10 mins):
(Date:6/27/2017)... Jun 27, 2017   NuEyes (NuEyes Technologies Inc.) ... to fuel its growth in helping the legally blind live ... Design Group), the leading developer of augmented, virtual and mixed ... The undisclosed funding amount was provided by strategic ... Angel, with offices in Abu Dhabi , ...
(Date:6/19/2017)... 19, 2017  Researchers from DRUGSCAN ® and ... host a live, complimentary webinar titled, "Untangling methods to ... the real world" on Wednesday June 28, 2017 from ... This webinar will feature interviews with recreational and dependent ... manipulation techniques abusers use to prepare opioid tablets for ...
(Date:6/14/2017)... 2017  ivWatch LLC, a medical device company focused ... therapy, is pleased to announce it was the Bronze ... Supplies and Equipment at the 2017 Medical Design Excellence ... industry. The award was presented by Medical Device and ... in New York during MD&M ...
Breaking Medicine Technology: